
Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer
Selinexor (Xpovio) maintenance therapy continued to demonstrate durable clinical benefit in patients with TP53 wild-type advanced or recurrent endometrial cancer, with benefits seen over placebo irrespective of mismatch repair status, according to long- …